49,401 Shares in Inhibrx, Inc. (NASDAQ:INBX) Purchased by Rangeley Capital LLC

Rangeley Capital LLC acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, Holdings Channel.com reports. The fund acquired 49,401 shares of the company’s stock, valued at approximately $761,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Inhibrx during the fourth quarter worth $348,000. Exchange Traded Concepts LLC purchased a new stake in Inhibrx during the fourth quarter worth about $148,000. Bank of New York Mellon Corp acquired a new stake in shares of Inhibrx during the fourth quarter worth about $792,000. Meridian Wealth Advisors LLC purchased a new position in shares of Inhibrx in the fourth quarter valued at approximately $385,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of Inhibrx in the fourth quarter valued at approximately $28,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Stock Up 0.4 %

Inhibrx stock opened at $14.10 on Thursday. The company has a fifty day simple moving average of $13.38 and a 200-day simple moving average of $14.57. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $35.42.

Inhibrx (NASDAQ:INBX) last announced its quarterly earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, equities research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.